89bio Presents New Analysis of Data from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) at American College of Cardiology’s Annual Scientific Session Together with World Congress of Cardiology

March 5, 2023

https://www.globenewswire.com/news-release/2023/03/04/2620617/0/en/89bio-Presents-New-Analysis-of-Data-from-Phase-2-ENTRIGUE-Trial-of-Pegozafermin-in-Patients-with-Severe-Hypertriglyceridemia-SHTG-at-American-College-of-Cardiology-s-Annual-Scienti.html

– Post hoc analysis data demonstrated pegozafermin treatment significantly reduced triglycerides and other atherogenic lipids in patients with SHTG regardless of their background lipid-modifying therapy status –

Read more at globenewswire.com

Related news for (ETNB)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.